Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELOXATIN vs KANAMYCIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.
Adjuvant treatment of stage III colon cancer after complete resection of primary tumor,Treatment of advanced colorectal cancer in combination with 5-fluorouracil and leucovorin
Short-term treatment of serious infections caused by susceptible strains of bacteria (e.g., Escherichia coli, Proteus species, Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species),Adjunctive therapy in staphylococcal infections,Mycobacterium tuberculosis infections (as second-line agent)
85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Terminal half-life of ultrafilterable platinum: ~10-27 hours (mean ~14 hours); total platinum: ~40-50 hours. Clinical context: prolonged exposure due to tissue binding.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (Cr Cl <10 m L/min).
Oxaliplatin undergoes rapid non-enzymatic biotransformation in plasma and tissues to form active platinum derivatives, primarily via displacement of the oxalate ligand. Minimal hepatic metabolism; elimination is predominantly renal.
Not metabolized; excreted unchanged by glomerular filtration.
Renal: ~54% of platinum excreted in urine within 48 hours; fecal: small amount (<2%); biliary excretion is minimal.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Platinum binds >90% to plasma proteins, mainly albumin and gamma-globulins; irreversible binding.
Low; approximately 0-10%, primarily to albumin.
Vd of ultrafilterable platinum: ~0.4-0.6 L/kg; total platinum: ~4-6 L/kg, indicating extensive tissue distribution.
0.2-0.4 L/kg; reflects distribution primarily into extracellular fluid.
Oral: Not bioavailable (unstable in GI tract); IV: 100%.
Intramuscular: ~100%; Oral: <1% (not absorbed); Ophthalmic: minimal systemic absorption (<1%).
Cr Cl ≥60 m L/min: No adjustment; Cr Cl 50-59 m L/min: No adjustment; Cr Cl 40-49 m L/min: Administer 85 mg/m2, but no data for 130 mg/m2; Cr Cl 30-39 m L/min: Administer 85 mg/m2 with caution, no data for 130 mg/m2; Cr Cl 20-29 m L/min: Administer 85 mg/m2 with extreme caution, no data for 130 mg/m2; Cr Cl <20 m L/min: Not recommended.
GFR 50-90 m L/min: administer every 24 hours. GFR 10-50 m L/min: administer every 24-72 hours. GFR <10 m L/min: administer every 72-96 hours. Dose adjustments based on serum concentrations.
Child-Pugh A: No adjustment required; Child-Pugh B: No adjustment required; Child-Pugh C: Use with caution; no specific dose reduction defined.
No dose adjustment required for hepatic impairment. Kanamycin is primarily renally eliminated.
Not approved for pediatric use. No established dosing guidelines.
Neonates: 7.5-10 mg/kg IV every 12 hours. Infants and children: 15 mg/kg/day IM or IV divided every 8-12 hours. Maximum total daily dose: 1.5 g.
No specific dose adjustment recommended based on age alone; monitor renal function and adjust according to calculated creatinine clearance.
Lower initial and maintenance doses due to age-related decrease in renal function. Monitor renal function and serum concentrations closely. Consider dosing based on ideal body weight and renal function.
Anaphylactic-like reactions to oxaliplatin have been reported, which may occur within minutes of administration and require immediate discontinuation and symptomatic treatment. Oxaliplatin should be discontinued if severe hypersensitivity occurs.
Boxed warnings: Neurotoxicity (ototoxicity vestibular and auditory), nephrotoxicity, and neuromuscular blockade. Risk increases with high doses, prolonged use, renal impairment, and concurrent use of other ototoxic/nephrotoxic drugs. Monitor renal function and drug levels. Avoid in pregnancy.
Hypersensitivity reactions (including anaphylaxis) have been reported and may be life-threatening. Discontinue permanently if severe reaction occurs.,Peripheral neuropathy, which may be acute (reversible) or chronic (persistent), is dose-limiting and requires dose adjustment or discontinuation.,Hepatotoxicity, including hepatic sinusoidal obstruction syndrome, has been reported. Monitor liver function.,Pulmonary toxicity, including pulmonary fibrosis, has been observed. Discontinue if interstitial lung disease is suspected.,Bleeding risk due to thrombocytopenia; monitor platelet counts.,Rhabdomyolysis has been reported; monitor for muscle pain/weakness.,Post-marketing reports of reversible posterior leukoencephalopathy syndrome (RPLS); discontinue if symptoms occur.
Ototoxicity (vestibular and auditory) can be irreversible, especially with renal impairment, high doses, prolonged therapy, or concurrent ototoxic drugs. Nephrotoxicity risk; monitor renal function and serum drug levels. Neuromuscular blockade risk, especially with anesthetics, neuromuscular blocking agents, or in patients with neuromuscular disorders. Superinfection, Clostridium difficile diarrhea. Use caution in elderly, dehydration, and pre-existing renal impairment.
History of severe hypersensitivity to oxaliplatin or any components of the formulation,Severe renal impairment (creatinine clearance <30 m L/min),Bone marrow suppression with baseline neutrophil count <1.5 × 10^9/L or platelet count <75 × 10^9/L,Pregnancy (can cause fetal harm)
Hypersensitivity to kanamycin or other aminoglycosides; myasthenia gravis (increased risk of neuromuscular blockade).
Avoid cold food and beverages for 48 hours post-infusion to prevent acute neuropathy exacerbation. No known specific food-drug interactions; however, avoid grapefruit juice if taking CYP3A4-metabolized drugs (not oxaliplatin itself). Maintain adequate hydration; no restriction with normal meals.
No significant food interactions known. Kanamycin absorption is not affected by food. However, maintain adequate hydration.
Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of action (DNA cross-linking). Use during pregnancy is contraindicated unless maternal benefit outweighs risk. First trimester exposure carries highest risk of major malformations; second and third trimester exposure may cause fetal growth restriction, myelosuppression, and neurotoxicity.
First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible bilateral hearing loss) and nephrotoxicity, especially with prolonged or high-dose therapy.
It is unknown whether oxaliplatin or its metabolites are excreted in human milk. Due to potential serious adverse reactions in nursing infants, including myelosuppression and neurotoxicity, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. No M/P ratio data available.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution in breastfeeding due to potential for infant ototoxicity and nephrotoxicity; monitor infant for diarrhea, rash, and hearing loss.
No established dosing adjustments for pregnancy. Physiological changes (increased volume of distribution, altered hepatic metabolism, enhanced renal clearance) may reduce drug exposure. However, due to teratogenicity, use is not recommended. If deemed necessary, therapeutic drug monitoring is not standard and dose adjustments should be made based on clinical response and toxicity, with cautious monitoring of side effects.
No standard dosing adjustment required for pregnancy; however, increased volume of distribution may require higher loading doses. Tight therapeutic drug monitoring indicated due to altered renal clearance.
Eloxatin (oxaliplatin) causes acute and chronic peripheral neuropathy; acute symptoms are triggered by cold exposure. Premedicate with antiemetics (e.g., aprepitant, dexamethasone, 5-HT3 antagonist) and avoid cold drinks or ice during infusion and for 48 hours thereafter. Monitor for laryngopharyngeal dysesthesia with cold exposure. Do not use aluminum-containing needles or IV sets as they degrade platinum compounds. Oxaliplatin is not compatible with chloride-containing solutions; dilute only in 5% dextrose in water. Assess renal function and reduce dose if Cr Cl < 30 m L/min.
Kanamycin is an aminoglycoside antibiotic used primarily for serious Gram-negative infections. Monitor peak and trough levels to avoid ototoxicity and nephrotoxicity; typical therapeutic peaks: 15-30 mcg/m L, troughs <5 mcg/m L. Avoid concurrent use with other nephrotoxic or ototoxic drugs (e.g., furosemide, vancomycin, cisplatin). Adjust dose in renal impairment using creatinine clearance. Intramuscular administration preferred; avoid rapid IV push. Use with caution in myasthenia gravis or Parkinson's disease due to neuromuscular blockade potential.
Avoid cold drinks, ice, and cold temperatures during and for 2 days after infusion to prevent severe tingling or throat discomfort.,Report any numbness, tingling, or pain in hands/feet that interferes with daily activities or does not improve between cycles.,Take anti-nausea medications as prescribed before each infusion; call your doctor if vomiting persists.,Watch for signs of allergic reaction: rash, hives, difficulty breathing, swelling of face/lips/tongue.,Do not touch infusion tubing or eat ice chips during treatment due to cold sensitivity.
Complete the entire course of therapy even if you feel better.,Report any hearing loss, tinnitus, dizziness, or changes in urination immediately.,Stay well hydrated unless instructed otherwise.,Avoid taking other medications without consulting your doctor, especially diuretics or other antibiotics.,This medication may cause nausea; take with food if tolerated.
No interactions on record
"Kanamycin, an aminoglycoside antibiotic, may reduce the renal clearance of Lornoxicam, a nonsteroidal anti-inflammatory drug (NSAID), by competitively inhibiting tubular secretion or altering renal perfusion. This interaction can lead to elevated serum levels of Lornoxicam, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may present with worsening renal function or NSAID-related side effects, especially in those with pre-existing renal compromise or dehydration."
"Kanamycin, an aminoglycoside antibiotic, increases the nephrotoxic potential of Cisplatin, a platinum-based chemotherapeutic agent, through additive damage to the proximal renal tubules. This synergistic effect elevates the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or those receiving other nephrotoxic drugs. Clinically, this interaction may lead to reduced renal function, electrolyte imbalances, and delayed elimination of both agents, potentially exacerbating systemic toxicity."
"The coadministration of Kanamycin and Vancomycin results in synergistic nephrotoxicity due to additive insult to the proximal renal tubules. Both aminoglycoside and glycopeptide antibiotics accumulate in the renal cortex, causing tubular cell necrosis and acute kidney injury (AKI). This interaction significantly increases the risk of renal impairment, potentially leading to irreversible kidney damage, particularly in patients with pre-existing renal compromise, advanced age, or prolonged therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELOXATIN vs KANAMYCIN SULFATE, answered by our medical review team.
ELOXATIN is a Platinum-Based Antineoplastic that works by Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.. KANAMYCIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELOXATIN and KANAMYCIN SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELOXATIN is: 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).. The standard adult dose of KANAMYCIN SULFATE is: 15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELOXATIN and KANAMYCIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELOXATIN is classified as Category C. Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of. KANAMYCIN SULFATE is classified as Category C. First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.